On a consolidated basis the Anil Ambani-led Reliance Communication reported a 3.1% increase in its net profit at Rs162 crore for the first quarter ended on 30 June 2012
Reliance Communications (RCom) said it has narrowed net loss to Rs252 crore on a standalone basis for April-June quarter compared to a loss of Rs272 crore in the corresponding period a year ago, reports PTI.
However, on a consolidated basis the Anil Ambani-led telecom firm reported a 3.1% increase in its net profit at Rs162 crore for the first quarter ended on 30 June 2012.
The company had reported a net profit of Rs157 crore for the same period a year ago.
The Indian telecom sector is going through a period of stiff competition and changes in regulatory environment, which are putting pressure on margins and profitability.
RCom said it continues to be free cash flow positive.
“RCom generated operational cash flow of Rs1,650 crore in the first quarter. This is the second full year of positive free cash flow for the company and this trend will continue in succeeding years,” RCom said in a statement.
On a standalone basis, the total income dropped to Rs2,794 crore in the first quarter compared to Rs3,002 crore in the April-June quarter in 2011, RCom informed the BSE in a filing.
On a consolidated basis, its total income during April-June 2012 grew by 8.5% to Rs5,264 crore compared to Rs4,849 crore posted in the same period in the previous financial year.
“We are happy to share a satisfying quarterly performance in a very tough competitive environment...we have been able to report very stable EBITDA margin of 31%, which is the highest in industry,” RCom President and CEO Gurdeep Singh told PTI.
“We want to express that we have been successful in achieving revenue per minute stability now consecutively for nine quarters, in spite of intense competition and over supply of minutes in the industry. We continue to lead data growth in the industry,” he added.
The investment bank cautioned that PSU banks like State Bank of India, which have a greater exposure to SME advances, are more susceptible to non-performing advances than private banks on account of uncertain monsoon and economic outlook
Commenting on the performance, Dr Hasit B Joshipura, managing director, GSK Pharma said, “Growth for the quarter was market competitive, with all the segments delivering strong growth”
GlaxoSmithKline Pharmaceuticals has posted a net profit from activities of Rs163.52 crore for the quarter ended 30 June 2012 as compared to Rs147.54 crore for the quarter ended 30 June 2011. Total Income has increased from Rs603.66 crore for the quarter ended 30 June 2011 to Rs699.88 crore for the quarter ended 30 June 2012.
In the second quarter, the company launched Uricostat for gout treatment. The company expanded its oncology portfolio by launching HycamtinTM to fulfil unmet needs for patients with advance cancers and relapsed small cell lung cancer (SCLC).
The company also introduced Volibris (Ambrisentan), a non-sulphonamide class endothelin receptor antagonist (ERA) used to treat pulmonary arterial hypertension (PAH).
During the quarter, a Metered Dose Inhaler (MDI) with dose counter was launched, which will help patients keep a correct count of drug doses taken. This technology has been introduced in Seretide Evohaler.
Commenting on the performance, Dr Hasit B Joshipura, managing director, GSK Pharma said, “Growth for the quarter was market competitive, with all the segments delivering strong growth.”